Arguing against the FDA's effort to retroactively fill a "substantial gap" in its regulatory framework for analyzing complex, naturally derived mixtures for exclusivity purposes, Omthera Pharmaceuticals Inc. petitioned the agency to grant five-year new chemical entity (NCE) exclusivity to its prescription fish oil drug Epanova.